

INFORMATION DISCLOSURE STATEMENT

(37 C.F.R. 1.56, 1.97, and 1.98)



SHEET 1 OF 2

ATTORNEY DOCKET

23164-1003

APPLICATION NO.

08/853,292

APPLICANT(S)

Tovey, Michael G.

FILING DATE

May 9, 1997

GROUP

1801 1676

U.S. PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
<i>MT</i>	A	4,605,555	8/86	Sato et al	424/85	
	B	4,820,514	4/89	Cummins	424/85.4	
	C	5,019,382	5/91	Cummins, Jr.	424/85.4	
	D	5,215,741	6/93	Young et al.	424/85.7	
	E	5,286,748	2/94	Eby, III	514/494	

FOREIGN PATENT DOCUMENTS

† EX'R INITIAL	* REF. #				TRANSLATION (YES/NO)
<i>MT</i>	F	CA 1,320,905	8/93	Canada	yes

OTHER DOCUMENTS

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
<i>MT</i>	G	Boguniewicz et al., "The Effect of Nebulized Recombinant Interferon- γ in Asthmatic Airways", <i>J. Allergy Clin. Immunol.</i> 95:133-135 (1995).
	H	Brod et al., "Oral Administration of IFN- α is Superior to Subcutaneous Administration of IFN- α in the Suppression of Chronic...", <i>Journal of Autoimmunity</i> 9:11-20 (1996).
	I	Douglas et al., "Prophylactic Efficacy of Intranasal Alpha ₂ -Interferon Against Rhinovirus Infections in the Family Setting" 314: 65-70 (1986).
	J	Hayden et al., "Intranasal Interferon α 2 for Prevention of Rhinovirus Infection and Illness", <i>Journal of Infectious Diseases</i> 148:543-550 (1983).
	K	Hayden et al., "Human Tolerance and Histopathologic Effects of Long Term Administration of Intranasal Interferon- α 2", <i>Journal of Infectious Diseases</i> 148:914-921 (1983).
	L	Hayden et al., "Prevention of Natural colds by Contact Prophylaxis with Intranasal Alpha ₂ -Interferon", <i>New England Journal Of Medicine</i> 314:71-75 (1986).
	M	Hayden et al., "Human Nasal Mucosal Responses to Topically Applied Recombinant Leukocyte A Interferon", <i>Journal of Infectious Diseases</i> 156:64-72 (1987).
	N	Iida et al., "Protective Activity of Recombinant Cytokines Against Sendai Virus and Herpes Simplex Virus (HSV) infections in mice", <i>Vaccine</i> 7:229-233 (1989).
	O	Matsuzawa et al., "Protective Effect of Mucosal Administration of Recombinant Human Macrophage Colony-Stimulating Factor...", <i>Vaccine</i> 15:85-89 (1997).
	P	Moore et al., "Inflammatory Markers in Bronchoalveolar Lavage Fluid of Standardbred Racehorses with Inflammatory...", <i>Equine Veterinary Journal</i> 29:142-147 (1997).
	Q	Oehling et al., "Suppression of the Immune System by Oral Glucocorticoid Therapy in Bronchial Asthma", <i>Allergy</i> 52:144-154.

DAVID L. FITZGERALD
PRIMARY EXAMINER
GROUP 1800

9/24/98

08/853, 292
AV 1646

M	R	Samo et al., "Efficacy and Tolerance of Intranasally Applied Recombinant Leukocyte A Interferon in Normal Volunteers", <i>Journal of Infectious Diseases</i> 148:535-542 (1983).
	S	Samo et al., "Intranasally Applied Recombinant Leukocyte A Interferon in Normal Volunteers. II.", <i>Journal of Infectious Diseases</i> 150:181-188 (1984).
	T	Soos et al., Oral Feeding of Interferon τ Can Prevent the Acute and Chronic Relapsing Forms of Experimental Allergic Encephalomyelitis", <i>Journal of Neuroimmunology</i> 75:43-50 (1997).
	U	Vriesendorp et al., "Oral Administration of Type I Interferon Modulates the Course of Experimental Allergic Neuritis", <i>Autoimmunity</i> 24:157-165 (1996).
D	V	Zielinska et al., "Comparison of the Long-Term Effects of Treatment with Oral and Parenteral...", <i>Archivum Immunologiae et Therapiae Experimentalis</i> 44:359-366 (1996).
EXAMINER'S SIGNATURE DAVID L. FITZGERALD PRIMARY EXAMINER GROUP 1800		DATE CONSIDERED 9/24/98
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.		

